- The shares of 10X Genomics (NASDAQ: TXG) have received a $100 price target from JPMorgan. These are the details.
The shares of 10X Genomics (NASDAQ: TXG) have received a $100 price target from JPMorgan. And JPMorgan analyst Tycho Peterson is maintaining an “Overweight” rating on the shares.
Peterson adjusted the rating after the company reported its first-quarter earnings. 10x Genomics reported a Q1 EPS of ($0.38), which was $0.07 less than analyst estimates of ($0.31). And the revenue for the quarter was $114.5 million compared to the consensus estimate of $113.34 million.
In terms of guidance, 10x Genomics expects FY2022 revenue of between $600 and $630 million, compared to the consensus of $614 million.
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.